Alexander Egeberg
Alexander Egeberg is an expert in Dermatology at Bispebjerg Hospital (Denmark). As of October 2026, ScienceLeadR ranks Alexander Egeberg in the top 1% of experts worldwide for Syphilis, Psoriasis and Skin Diseases, Papulosquamous. Alexander Egeberg has authored 517 publications, the most recent in 2026, and is an investigator in 11 clinical trials, 1 of them ongoing. SLR score: 1,975 (community average: 125). How the SLR is computed.
LeadR Profile
Dermatology
Subspecialties: Public Health - Immunology - Infectiology
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2012 - 2026
Number : 517
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Risk of arthritis in patients with hidradenitis suppurativa: A population-based cohort study. PMID 42828447 — comorbidity, hidradenitis suppurativa, arthritis, cohort studies, skin diseases, hidradenitis | J Eur Acad Dermatol Venereol | 2026 | 0 |
| Glucagon-like peptide-1 receptor agonists in hidradenitis suppurativa: A nationwide cohort study. PMID 42828450 — diabetes mellitus, glucagon-like peptide 1, comorbidity, glucagon-like peptide-1 receptor, exenatide, surgical procedures, operative, cardiovascular diseases, hidradenitis suppurativa, cohort studies, skin diseases, hidradenitis, liraglutide, obesity, risk factors, glucagon, therapeutics, psoriasis, glucagon-like peptides, semaglutide | J Eur Acad Dermatol Venereol | 2026 | 0 |
| Long-term disease progression in adult atopic dermatitis: A 6-year observational study of severity and treatment patterns. PMID 42640864 — dermatitis, disease progression, skin diseases, signs and symptoms, therapeutics, mental health, dermatitis, atopic | Dermatology | 2026 | 0 |
| Drug survival of biologic treatments for psoriasis and psoriatic arthritis in Denmark, 2018-23: a nationwide register-based cohort study. PMID 42540015 — arthritis, psoriatic, ustekinumab, pharmaceutical preparations, arthritis, cohort studies, therapeutics, psoriasis, infliximab, survival rate | Skin Health Dis | 2026 | 0 |
| Serological biomarkers of extracellular matrix proteins are associated with hidradenitis suppurativa disease severity and treatment response. PMID 42539965 — extracellular matrix proteins, hidradenitis suppurativa, biomarkers, hidradenitis, therapeutics, tissues, basement membrane, extracellular matrix, membranes | Skin Health Dis | 2026 | 0 |
Clinical Studies 11
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Ongoing Clinical Trials
Ongoing trial started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| Extending Omalizumab Treatment Intervals in Patients With Chronic Spontaneous Urticaria NCT05916937 — chronic urticaria, omalizumab, urticaria, therapeutics | Phase 4 | Recruiting | 2024 |
LeadR Networks
Main global connection map